Jaume Farrés

This paper identifies a covalent irreversible inhibitor, Z34, that binds to ALDH1A3 in two distinct conformations at the active-site cysteine, showing promise for anticancer drug development.

This study detects ALDH1A3 enzymatic activity in exosomes from breast cancer cell lines using nano-flow cytometry, providing functional evidence of its presence in cancer-derived exosomes.

This paper introduces a fluorometric assay for detecting reductase activity using MONOL-41, showing improved sensitivity and lower detection limits compared to NADPH-based methods.

This study identifies ALDH1A3 as a therapeutic target in aggressive breast cancers and develops ABD0171, a selective inhibitor showing antitumor and antimetastatic effects.